Taken together, this study establishes SIRT1-modified hUCMSC administration as a combination approach with therapeutic potential for the treatment of PD-induced peritoneal damage and peritoneal fibrosis. This evidence concerns the gene SIRT1 and Peritoneal Fibrosis.